Canadian researchers begin clinical trials of tuberculosis vaccine for COVID-19
University Health Network researchers in Toronto are beginning a clinical trial of 3,600 front-line workers to determine if Bacillus Calmette–Guerin (BCG), a vaccine typically given against tuberculosis, can be sufficiently immune-boosting that it can decrease the frequency and severity of COVID-19 among participants. The concept for the trial emerged when researchers noted that some jurisdictions with high BCG vaccination rates also had lower COVID-19 infection rates. Similar trials are being conducted internationally in Australia, Europe and Mexico. While the vaccine does not offer immunization against COVID-19, its immune-boosting effect could potentially become another tool, similar to masking and physical distancing, that protects vulnerable populations.
Published: October 6, 2020
CTV NewsRead Article